Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Nov 7;22(41):9044-9056.
doi: 10.3748/wjg.v22.i41.9044.

Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection

Nina Weiler  1 , Stefan Zeuzem  1 , Martin-Walter Welker  1
Affiliations
Review

Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection

Nina Weiler et al. World J Gastroenterol. .

Abstract

Chronic hepatitis C is a major reason for development of cirrhosis and hepatocellular carcinoma and a leading cause for liver transplantation. The development of direct-acting antiviral agents lead to (pegylated) interferon-alfa free antiviral therapy regimens with a remarkable increase in sustained virologic response (SVR) rates and opened therapeutic options for patients with advanced cirrhosis and liver graft recipients. This concise review gives an overview about most current prospective trials and cohort analyses for treatment of patients with liver cirrhosis and liver graft recipients. In patients with compensated cirrhosis Child-Pugh-Turcotte (CTP) class A, all approved agents are safe and SVR rates do not significantly differ from patients without cirrhosis in general. In patients with decompensated cirrhosis CTP class B or C, daclastasvir, ledipasvir, velpatasvir, and sofosbuvir are approved, and SVR rates higher than 90% can be achieved. Especially for patients with a model of end stage liver disease score higher than 15 and therefore eligible for liver transplantation, data is scarce. Reported SVR rates in patients with cirrhosis CTP class C are lower compared to patients with a less severe liver disease. In liver transplant recipients with a maximum of CTP class A, SVR rates are comparable to patients without LT. Patients with decompensated graft cirrhosis should be treated on an individual basis.

Keywords: Cirrhosis; Direct antiviral agents; Hepatitis C; Interferon-free antiviral treatment; Liver transplantation.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: Weiler N, Consultancies/speaker’s bureau for Astellas, Novartis; Zeuzem S, Consultancies/speaker’s bureau for Abbvie, BMS, Gilead, Janssen, Merck; Welker MW, Consultancies/speaker’s fees: AbbVie, Amgen, Bayer, BMS, Gilead, Novartis, Roche. Travel Support: AbbVie, Astellas, Bayer, BMS, Novartis, Janssen, Roche.

References

    1. Hepatitis C - Fact sheet N 164. In: Organisation WH, editor. World Health Organization: 2014.
    1. Allison RD, Tong X, Moorman AC, Ly KN, Rupp L, Xu F, Gordon SC, Holmberg SD. Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006-2010. J Hepatol. 2015;63:822–828. - PMC - PubMed
    1. van der Meer AJ, Wedemeyer H, Feld JJ, Dufour JF, Zeuzem S, Hansen BE, Janssen HL. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. JAMA. 2014;312:1927–1928. - PubMed
    1. Adam R, Karam V, Delvart V, O’Grady J, Mirza D, Klempnauer J, Castaing D, Neuhaus P, Jamieson N, Salizzoni M, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR) J Hepatol. 2012;57:675–688. - PubMed
    1. Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, Trinchet JC, Beaugrand M, Chevret S. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut. 2000;47:131–136. - PMC - PubMed

MeSH terms